...
rnac-img

Cartesian Therapeutics Inc., Common Stock

RNAC

NMQ

$16.92

-$1.39

(-7.59%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$430.27M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
212.47K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.83
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$11.66 L
$41.87 H
$16.92

About Cartesian Therapeutics Inc., Common Stock

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameRNACSectorS&P500
1-Week Return-28.88%-2.06%-0.55%
1-Month Return-8.89%-1.92%2.72%
3-Month Return8.25%-10.4%7.66%
6-Month Return-22.24%-4.6%10.15%
1-Year Return-22.65%4.06%27.53%
3-Year Return-82.75%1.94%32.31%
5-Year Return-61.37%36.48%89.2%
10-Year Return-95.97%97.46%194.59%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue6.68M16.60M85.08M110.78M26.00M[{"date":"2019-12-31","value":6.03,"profit":true},{"date":"2020-12-31","value":14.98,"profit":true},{"date":"2021-12-31","value":76.8,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":23.47,"profit":true}]
Cost of Revenue42.74M--2.04M1.55M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":4.77,"profit":true},{"date":"2023-12-31","value":3.63,"profit":true}]
Gross Profit6.68M16.60M85.08M108.74M24.45M[{"date":"2019-12-31","value":6.14,"profit":true},{"date":"2020-12-31","value":15.26,"profit":true},{"date":"2021-12-31","value":78.24,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":22.49,"profit":true}]
Gross Margin100.00%100.00%100.00%98.16%94.03%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.16,"profit":true},{"date":"2023-12-31","value":94.03,"profit":true}]
Operating Expenses57.10M73.42M89.67M96.24M110.87M[{"date":"2019-12-31","value":51.51,"profit":true},{"date":"2020-12-31","value":66.22,"profit":true},{"date":"2021-12-31","value":80.88,"profit":true},{"date":"2022-12-31","value":86.81,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(52.45M)(56.82M)(4.60M)14.54M(86.42M)[{"date":"2019-12-31","value":-360.81,"profit":false},{"date":"2020-12-31","value":-390.84,"profit":false},{"date":"2021-12-31","value":-31.62,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-594.41,"profit":false}]
Total Non-Operating Income/Expense(4.41M)(13.61M)(7.97M)17.20M(155.13M)[{"date":"2019-12-31","value":-25.66,"profit":false},{"date":"2020-12-31","value":-79.13,"profit":false},{"date":"2021-12-31","value":-46.32,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-901.85,"profit":false}]
Pre-Tax Income(55.35M)(68.88M)(9.72M)34.77M(238.71M)[{"date":"2019-12-31","value":-159.19,"profit":false},{"date":"2020-12-31","value":-198.09,"profit":false},{"date":"2021-12-31","value":-27.96,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-686.54,"profit":false}]
Income Taxes1.86M1.65M15.97M(609.00K)(19.00M)[{"date":"2019-12-31","value":11.62,"profit":true},{"date":"2020-12-31","value":10.3,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-3.81,"profit":false},{"date":"2023-12-31","value":-119,"profit":false}]
Income After Taxes(57.21M)(70.52M)(25.69M)35.38M(219.71M)[{"date":"2019-12-31","value":-161.69,"profit":false},{"date":"2020-12-31","value":-199.33,"profit":false},{"date":"2021-12-31","value":-72.61,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-621.02,"profit":false}]
Income From Continuous Operations(55.35M)(68.88M)(25.69M)35.38M(219.71M)[{"date":"2019-12-31","value":-156.45,"profit":false},{"date":"2020-12-31","value":-194.68,"profit":false},{"date":"2021-12-31","value":-72.61,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-621.02,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(55.35M)(68.88M)(25.69M)35.38M(219.71M)[{"date":"2019-12-31","value":-156.45,"profit":false},{"date":"2020-12-31","value":-194.68,"profit":false},{"date":"2021-12-31","value":-72.61,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-621.02,"profit":false}]
EPS (Diluted)(1.24)(0.69)(0.31)0.28(0.34)[{"date":"2019-12-31","value":-442.86,"profit":false},{"date":"2020-12-31","value":-246.43,"profit":false},{"date":"2021-12-31","value":-110.71,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-121.43,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

RNAC
Cash Ratio 10.24
Current Ratio 10.70

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RNAC
ROA (LTM) -10.95%
ROE (LTM) -7029.26%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RNAC
Debt Ratio Lower is generally better. Negative is bad. 1.00
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.00

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RNAC
Trailing PE NM
Forward PE 25.45
P/S (TTM) 8.97
P/B 572.17
Price/FCF 57
EV/R 4.71
EV/Ebitda NM
PEG NM

FAQs

What is Cartesian Therapeutics Inc. share price today?

Cartesian Therapeutics Inc. (RNAC) share price today is $16.92

Can Indians buy Cartesian Therapeutics Inc. shares?

Yes, Indians can buy shares of Cartesian Therapeutics Inc. (RNAC) on Vested. To buy Cartesian Therapeutics Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RNAC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Cartesian Therapeutics Inc. be purchased?

Yes, you can purchase fractional shares of Cartesian Therapeutics Inc. (RNAC) via the Vested app. You can start investing in Cartesian Therapeutics Inc. (RNAC) with a minimum investment of $1.

How to invest in Cartesian Therapeutics Inc. shares from India?

You can invest in shares of Cartesian Therapeutics Inc. (RNAC) via Vested in three simple steps:

  • Click on Sign Up or Invest in RNAC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Cartesian Therapeutics Inc. shares
What is Cartesian Therapeutics Inc. 52-week high and low stock price?

The 52-week high price of Cartesian Therapeutics Inc. (RNAC) is $41.87. The 52-week low price of Cartesian Therapeutics Inc. (RNAC) is $11.66.

What is Cartesian Therapeutics Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Cartesian Therapeutics Inc. (RNAC) is

What is Cartesian Therapeutics Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Cartesian Therapeutics Inc. (RNAC) is 572.17

What is Cartesian Therapeutics Inc. dividend yield?

The dividend yield of Cartesian Therapeutics Inc. (RNAC) is 0.00%

What is the Market Cap of Cartesian Therapeutics Inc.?

The market capitalization of Cartesian Therapeutics Inc. (RNAC) is $430.27M

What is Cartesian Therapeutics Inc.’s stock symbol?

The stock symbol (or ticker) of Cartesian Therapeutics Inc. is RNAC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top